Selank Family: Selank (CAS 129954-34-3) vs NA-Selank (N-Acetyl Selank) vs Tuftsin (CAS 9063-57-4) — Complete Research Guide

1. Introduction: The Selank Peptide Family

The Selank family represents one of the most fascinating examples of rational peptide drug design in modern pharmacology. At its core, this family spans three interconnected molecules — Tuftsin, Selank, and N-Acetyl Selank (NA-Selank) — each representing a distinct stage in the evolution from a naturally occurring immune peptide to a CNS-active anxiolytic compound with enhanced metabolic stability.

The story begins with Tuftsin (CAS 9063-57-4), an endogenous tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc domain of immunoglobulin G (IgG). Discovered in 1970 by Victor A. Najjar and Keisuke Nishioka at Tufts University, tuftsin is the body's natural activator of phagocytic cells — macrophages, monocytes, and neutrophils. However, its therapeutic utility is severely limited by an extraordinarily short plasma half-life measured in seconds.

In the 1990s, researchers at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences addressed this limitation by extending tuftsin's C-terminus with a Pro-Gly-Pro tripeptide, creating Selank (CAS 129954-34-3) — a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with dramatically improved metabolic stability and an entirely new spectrum of CNS activity, including anxiolytic and nootropic effects. Selank was approved in Russia in 2009 as a prescription anxiolytic nasal spray (brand name Selanc) for generalized anxiety disorder (GAD).

The most recent iteration, N-Acetyl Selank (NA-Selank), applies N-terminal acetylation — a well-established pharmaceutical modification — to further protect the peptide from aminopeptidase degradation. While NA-Selank has no independent clinical validation, its structural logic is sound, and it represents the next generation of stability-optimized tuftsin analogs for research applications.

2. Tuftsin (CAS 9063-57-4) — The Endogenous Parent Molecule

Discovery and Biosynthesis

Tuftsin was first identified in 1970 by Victor A. Najjar and Keisuke Nishioka at the Tufts University School of Medicine in Boston, from which the peptide derives its name. It is not synthesized de novo but is generated through a unique two-step proteolytic processing pathway from the heavy chain of immunoglobulin G (IgG).

The active tetrapeptide corresponds to residues 289–292 of the CH2 domain of the IgG Fc region, located within a larger fragment called leukokinin. Liberation of the active tetrapeptide requires two sequential enzymatic cleavages:

This unique biosynthetic pathway — requiring both splenic processing and neutrophil membrane enzymatic activity — explains why splenectomy reduces circulating tuftsin levels by 60–70%, as demonstrated by Spirer et al. (1980) in 16 splenectomized patients. This organ dependency is unique among known peptide hormones and explains the well-known immunological vulnerability of asplenic patients to overwhelming infections, particularly with encapsulated bacteria.

Mechanism of Action: Immune Activation

Tuftsin's primary biological function is the stimulation of phagocytosis. The tetrapeptide binds to specific, saturable receptors on the surface of phagocytic cells with a dissociation constant (Kd) of approximately 10 nM, with an estimated 50,000–100,000 binding sites per cell. This high receptor density enables robust immune responses even at low tuftsin concentrations.

Downstream signaling events following tuftsin receptor engagement include:

• Calcium mobilization from intracellular stores
• Protein kinase C (PKC) activation
• Enhanced actin polymerization and pseudopod extension
• NADPH oxidase activation (respiratory burst → superoxide production)
• Increased membrane ruffling and particle engulfment
• IL-1 production by macrophages (dose-dependent, significant at 1 µM, maximal at 10–50 µM)

Key Biological Activities

• Phagocytosis enhancement: Active at concentrations as low as 10 nM; half-maximal stimulation at ~0.1–1 µM; maximal phagocytosis enhancement at 10–100 µM
• Respiratory burst stimulation: Dose-dependent NADPH oxidase-mediated superoxide production in human neutrophils (active from 0.1 µM, maximal at 10–100 µM)
• Tumoricidal activity: Enhances macrophage tumor-killing activity against K562 targets in a dose-dependent manner (0.1–100 µM)
• Chemotaxis and motility: Enhances directed migration and random motility of phagocytic cells
• Antibody formation influence: Modulates adaptive immune responses

3. Selank (CAS 129954-34-3) — The Stabilized Heptapeptide Analog

Design Rationale: From Immune Peptide to CNS-Active Drug

Selank was developed at the Institute of Molecular Genetics (IMG) in Moscow in cooperation with the V.V. Zakusov Research Institute of Pharmacology. The design strategy was elegantly simple: take the biologically active tuftsin sequence (Thr-Lys-Pro-Arg) and extend it at the C-terminus with three natural L-amino acids (Pro-Gly-Pro) to improve metabolic stability and enable CNS penetration.

This modification is pharmacologically significant because it did not merely extend half-life — it introduced an entirely new category of bioactivity. Native tuftsin has no documented anxiolytic or nootropic effects. The Pro-Gly-Pro extension conferred conformational properties that enabled interaction with CNS targets, transforming a peripheral immunomodulator into a dual-action neuroimmune peptide.

Mechanism of Action: Multi-System Neuroimmune Modulation

Selank exerts its pharmacological effects through multiple converging mechanisms that distinguish it from both classical anxiolytics and pure immunomodulators:

① GABAergic Modulation (Primary Anxiolytic Mechanism)

Selank's primary anxiolytic mechanism involves indirect allosteric modulation of GABA-A receptors. Rather than directly binding to the benzodiazepine site, Selank alters the expression of GABA-A receptor subunit genes, enhancing the receptor's sensitivity to endogenous GABA.

• Volkova et al. (2016) found that Selank significantly altered expression of 45 of 84 examined neurotransmission-related genes in the rat frontal cortex within 1 hour post-administration
• Affected genes included GABA-A receptor subunits (alpha-1, alpha-2, alpha-5, beta-2, delta, gamma-1), transporters, and ion channels
• This mechanism produces anxiolytic effects comparable to benzodiazepines but without sedation, tolerance, or dependence

② BDNF Upregulation (Nootropic Mechanism)

Semenova et al. (2009) demonstrated that intranasal Selank at 250 and 500 µg/kg elevated BDNF mRNA in the rat hippocampus at 3 hours and BDNF protein at 24 hours post-administration. BDNF is the key neurotrophin supporting synaptic plasticity, neuronal survival, and long-term potentiation (LTP) — the cellular basis for learning and memory.

③ Enkephalinase Inhibition

Selank dose-dependently inhibits the enzymatic hydrolysis of enkephalins in human serum with an IC₅₀ of approximately 15–20 µM, making it more potent than classical peptidase inhibitors bacitracin and puromycin. By preserving endogenous enkephalin levels, Selank enhances opioidergic tone, contributing to its anxiolytic and mood-stabilizing properties. Notably, only the heptapeptide and its pentapeptide fragments showed this inhibitory effect; smaller fragments (including tuftsin itself) did not.

④ Monoaminergic Modulation

• Serotonin: Activated 5-HT metabolism in hypothalamus and caudal brain stem (30 min–2 h); restorative action on serotonin-depleted models
• Dopamine: Strain-dependent modulation of dopamine metabolites (DOPAC, HVA) in frontal cortex and hippocampus
• Norepinephrine: Increased levels in hypothalamus (0.3 mg/kg dose)

⑤ Immunomodulatory Activity (Inherited from Tuftsin)

Selank retains and extends tuftsin's immunomodulatory properties. A single injection (100 µg/kg) altered expression of 34 of 84 inflammation-related genes in the mouse spleen within 24 hours (Kolomin et al., 2011). Key findings include:

• IL-6 regulation: Reduces elevated IL-6 under stress conditions; normalizes rather than suppresses
• Complement C3: 3-fold decrease in mRNA within 3 hours, then normalization by 24 hours
• Bcl6 upregulation: Master transcription factor for B-cell differentiation
• Antiviral activity: Documented against influenza A (H3N2), HSV-1, HSV-2, and CMV

Clinical Evidence (Russian Registration)

Selank was approved in Russia in 2009 as Selanc 0.15% nasal drops for generalized anxiety disorder. Key clinical findings include:

• Zozulia et al. (2008): 62 patients with GAD; Selank (n=30) vs. medazepam (n=32); comparable anxiolytic efficacy on Hamilton, Zung, and CGI scales; Selank additionally produced antiasthenic and psychostimulant effects not seen with medazepam
• Dose-response study (N=20): Selank 2,700 µg/day intranasally reduced HAM-A scores from 20.3 → 7.0 in rapid responders by Day 3 (p < 0.01) and from 16.1 → 6.2 in conventional responders by Day 14 (p < 0.01)
• Phobic anxiety study (2014, N=60): Anxiolytic effects persisted one week after final dose
• Bogdanov et al. (2020): Resting-state fMRI in healthy volunteers showed distinct amygdala connectivity changes at 5 and 20 minutes post intranasal dosing

4. NA-Selank (N-Acetyl Selank) — The Next-Generation Stabilized Analog

What Is N-Terminal Acetylation?

N-terminal acetylation is one of the most common and impactful post-translational modifications in peptide chemistry. The process involves capping the free α-amino group at the N-terminus of a peptide with an acetyl group (CH₃CO-). This seemingly minor modification has profound effects on peptide behavior:

Why N-Acetylation Matters for Selank

The primary site of enzymatic attack on Selank is the N-terminal threonine residue, which is vulnerable to aminopeptidases — enzymes that cleave peptides from the N-terminus. By capping this terminus with an acetyl group, NA-Selank gains several advantages:

• Enhanced enzymatic stability: The acetyl group prevents aminopeptidase recognition and cleavage, significantly extending the peptide's functional duration in biological matrices
• Improved membrane association: N-acetylation increases hydrophobicity, reducing electrostatic repulsion at membrane surfaces and potentially supporting more efficient transport across lipid-rich environments
• Refined conformation: The acetyl cap subtly constrains the N-terminal conformation, producing a more defined molecular structure that may improve predictability in research settings
• Potentially reduced dosing frequency: Due to extended stability, NA-Selank may achieve equivalent pharmacological effects at lower doses, potentially shifting the dose-response curve leftward

Pharmacodynamic Profile: Expected Equivalence to Selank

Because N-acetylation is primarily a pharmacokinetic modification rather than a pharmacodynamic one, NA-Selank is expected to share the same mechanism of action as parent Selank:

• Allosteric modulation of GABA-A receptors (same active pharmacophore)
• BDNF upregulation in hippocampal and cortical tissue
• Enkephalinase inhibition (IC₅₀ ~15–20 µM)
• Serotonergic and dopaminergic modulation
• Immunomodulatory activity via tuftsin-derived sequence

NA-Selank vs. NA-Selank Amidate

Some suppliers offer N-Acetyl Selank Amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂), which adds C-terminal amidation in addition to N-terminal acetylation. This dual modification protects against both aminopeptidases (N-terminal) and carboxypeptidases (C-terminal), potentially offering the highest metabolic stability in the Selank family. However, like NA-Selank, this variant has no independent published research.

5. Structural Evolution & Design Rationale

The progression from Tuftsin → Selank → NA-Selank represents a masterclass in rational peptide stabilization. Each modification addresses a specific enzymatic vulnerability while preserving (or enhancing) the biological activity of the parent molecule.

The Enzymatic Vulnerability Map

This stepwise protection strategy — C-terminal extension first (Selank), then N-terminal capping (NA-Selank), then dual-end protection (NA-Selank Amidate) — illustrates how peptide chemists systematically address each metabolic vulnerability without altering the core pharmacophore (Thr-Lys-Pro-Arg).

6. Mechanism of Action Comparison

While all three compounds share the tuftsin core sequence (Thr-Lys-Pro-Arg), their mechanisms of action diverge significantly based on structural modifications that affect receptor engagement, CNS penetration, and downstream signaling.

Mechanism	Tuftsin	Selank	NA-Selank
GABA-A Modulation	✗ Not documented	✓ Indirect allosteric; 45/84 genes altered in frontal cortex	✓ Expected (same pharmacophore)
BDNF Upregulation	✗ Not documented	✓ Hippocampal BDNF mRNA ↑ at 3h; protein ↑ at 24h	✓ Expected equivalent
Enkephalinase Inhibition	✗ Not active (tetrapeptide too small)	✓ IC₅₀ ~15–20 µM (more potent than bacitracin)	✓ Expected equivalent
Phagocytosis Activation	✓ Primary activity (Kd ~10 nM)	✓ Retained (tuftsin heritage)	✓ Expected equivalent
IL-6 Regulation	✓ Macrophage IL-1 stimulation	✓ Normalizes IL-6 (↑ when low, ↓ when high)	✓ Expected equivalent
Serotonin Modulation	✗ Not documented	✓ Activates 5-HT metabolism in hypothalamus	✓ Expected equivalent
Dopamine Modulation	✗ Not documented	✓ Strain-dependent DOPAC/HVA changes	✓ Expected equivalent
Respiratory Burst	✓ NADPH oxidase activation	✓ Retained (tuftsin heritage)	✓ Expected equivalent
Antiviral Activity	✗ Not documented	✓ Influenza A, HSV-1/2, CMV	✓ Expected equivalent
CNS Penetration	✗ Does not cross BBB	✓ Via intranasal nose-to-brain pathway	✓ Potentially improved
Anxiolytic Activity	✗ None documented	✓ Clinically validated (Russia)	✓ Expected (no independent data)
Nootropic Activity	✗ None documented	✓ BDNF-mediated cognitive enhancement	✓ Expected (no independent data)

7. Pharmacokinetics & Stability Comparison

Parameter	Tuftsin	Selank	NA-Selank
Molecular Weight	500.59 Da	751.87 Da	~793.9 Da
Amino Acid Count	4 (tetrapeptide)	7 (heptapeptide)	7 + acetyl group
N-Terminal Protection	✗ Free (vulnerable)	✗ Free (vulnerable)	✓ Acetylated (protected)
C-Terminal Protection	✗ Free (vulnerable)	✓ Pro-Gly-Pro extension	✓ Pro-Gly-Pro extension
Plasma Half-life	Seconds to low minutes	~2–5 minutes	Estimated 3–10× longer than Selank
BBB Penetration	Negligible	Yes (intranasal nose-to-brain)	Potentially improved
Primary Route	IV / IP (research)	Intranasal (clinical) / IP (research)	Intranasal (research)
Nasal Absorption	N/A (not used intranasally)	Standard	Potentially enhanced (↑ lipophilicity)
Receptor-Mediated Uptake	✓ Tuftsin receptor (Kd ~10 nM)	✓ Retained + CNS targets	✓ Expected equivalent
Storage (Lyophilized)	-20°C, 2 years	-20°C, up to 2 years	-20°C, up to 2 years
Storage (Reconstituted)	2-8°C, 1 month	2-8°C, 14–21 days (light-sensitive)	2-8°C, 14–30 days (estimated)
Dosing Frequency (Research)	N/A (impractical for systemic use)	2–3 times daily (intranasal)	Potentially 1–2 times daily

Why Half-Life Matters for Research Design

The dramatic difference in metabolic stability across the three compounds has direct implications for experimental design:

• Tuftsin's seconds-long half-life makes it impractical for systemic studies; most tuftsin research uses high-dose bolus injections or in vitro models
• Selank's minutes-long half-life is sufficient for intranasal dosing due to the direct nose-to-brain transport pathway, which bypasses systemic first-pass degradation
• NA-Selank's projected extended half-life could enable lower doses, reduced frequency, and longer observation windows — particularly valuable for chronic stress and neuroplasticity protocols

8. Full Head-to-Head Comparison Table

Parameter	Tuftsin	Selank	NA-Selank
CAS Number	9063-57-4	129954-34-3	N/A (research compound)
Sequence	Thr-Lys-Pro-Arg	Thr-Lys-Pro-Arg-Pro-Gly-Pro	Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular Formula	C₂₁H₄₀N₈O₆	C₃₃H₅₇N₁₁O₉	C₃₅H₅₉N₁₁O₁₀ (estimated)
Molecular Weight	500.59 Da	751.87 Da	~793.9 Da (estimated)
Origin	Endogenous (IgG Fc fragment)	Synthetic (tuftsin + Pro-Gly-Pro)	Synthetic (Selank + N-acetyl)
Discovery/Development	Najjar & Nishioka, 1970	IMG Russian Academy, 1990s	Research community, ~2010s
Primary Activity	Immunomodulatory (phagocytosis)	Anxiolytic + Nootropic + Immunomodulatory	Expected same as Selank
CNS Activity	None (no BBB penetration)	Anxiolytic, nootropic, neuroprotective	Expected equivalent
Immune Activity	Primary (phagocytosis, respiratory burst)	Retained (IL-6, cytokine modulation)	Expected equivalent
Clinical Approval	None	Russia (2009, GAD)	None
Published Studies	Extensive (preclinical + early clinical)	Extensive (Russian clinical trials)	None (independent)
Best Research Use Case	Immune cell activation studies, phagocytosis assays	Anxiety, cognition, neuroimmune interaction studies	Extended-duration protocols requiring peptide stability
Purity Standard (NutraBiotech)	≥98% (HPLC)	≥98% (HPLC)	≥98% (HPLC)

9. Research Applications by Field

Each compound in the Selank family occupies a distinct niche in the research landscape. Understanding which compound to select for a given research question is critical for experimental success.

Research Field	Recommended Compound	Rationale	Evidence Level
Anxiety / Anxiolytic Mechanisms	Selank or NA-Selank	GABA-A modulation without sedation; Russian clinical validation	Strong (clinical)
Cognitive Enhancement / Nootropics	Selank or NA-Selank	BDNF upregulation; memory and learning paradigms	Moderate (preclinical + early clinical)
Neuroimmune Interaction	Selank	Dual CNS + immune activity; 34/84 gene expression changes	Strong (preclinical)
Phagocytosis / Innate Immunity	Tuftsin	Primary phagocytosis activator; Kd ~10 nM receptor binding	Strong (preclinical)
Macrophage Activation	Tuftsin	Direct receptor-mediated activation; IL-1 stimulation	Strong (preclinical)
Antiviral Research	Selank	Documented activity vs. influenza A, HSV, CMV	Moderate (preclinical)
Stress / HPA Axis Research	Selank or NA-Selank	Corticosterone suppression; stress resilience models	Moderate (preclinical)
Enkephalin / Opioid System	Selank	Enkephalinase inhibition (IC₅₀ ~15–20 µM)	Moderate (in vitro)
Peptide Stability / PK Studies	NA-Selank	N-acetylation as stability optimization model	Early (theoretical/extrapolated)
Sepsis / Infection Models	Tuftsin	Tuftsin-based nanoparticles in sepsis models (2025)	Early (preclinical)
Benzodiazepine Alternatives	Selank	Comparable anxiolysis without sedation/dependence	Moderate (clinical, Russian)
Chronic Dosing Protocols	NA-Selank	Extended half-life for reduced dosing frequency	Theoretical (no independent data)

10. Sourcing & Quality Standards for Research Peptides

When sourcing Selank family peptides for research, quality and documentation are paramount. The following criteria should guide procurement decisions:

Essential Quality Criteria

Criterion	Standard	Why It Matters
Purity	≥98% (HPLC verified)	Impurities can confound receptor binding assays and behavioral studies
COA (Certificate of Analysis)	Required for every batch	Confirms identity, purity, and absence of contaminants
MSDS	Required	Safety handling information for laboratory use
Mass Spectrometry	Required (molecular weight confirmation)	Verifies correct peptide sequence and modification (e.g., acetylation)
Synthesis Method	Solid-Phase Peptide Synthesis (SPPS)	Ensures batch-to-batch consistency and correct stereochemistry
Physical Form	Lyophilized powder	Maximum stability during shipping and storage
Storage Conditions	-20°C (lyophilized); 2–8°C (reconstituted)	Peptides are temperature-sensitive; improper storage degrades activity
Packaging	Vacuum-sealed, light-protected	Selank is light-sensitive; proper packaging preserves integrity

🚨 Red Flags When Sourcing Peptides

11. Frequently Asked Questions

12. Conclusion & Key Takeaways

The Selank family — spanning Tuftsin, Selank, and NA-Selank — illustrates how rational peptide engineering can transform a short-lived endogenous immune peptide into a clinically validated CNS-active drug and, subsequently, into a next-generation research compound with optimized pharmacokinetics.

Compound	Greatest Strength	Best Research Application
Tuftsin	Endogenous authenticity; direct phagocyte receptor binding	Innate immunity, phagocytosis, macrophage activation studies
Selank	Clinically validated anxiolytic without sedation/dependence	Anxiety, cognition, neuroimmune interaction, BDNF research
NA-Selank	Enhanced metabolic stability via N-terminal protection	Extended-duration protocols; stability-optimized PK studies

Final Summary

• Tuftsin (CAS 9063-57-4) is the endogenous starting point — a potent immunomodulator with a half-life too short for practical systemic therapeutic use and no CNS activity
• Selank (CAS 129954-34-3) is the clinically validated evolution — a Russian-approved anxiolytic with dual neuroimmune activity, GABA-A modulation, BDNF upregulation, and no benzodiazepine-like side effects
• NA-Selank is the pharmacokinetically optimized next generation — offering theoretical stability advantages through N-terminal acetylation, but lacking independent clinical validation
• All three share the tuftsin pharmacophore (Thr-Lys-Pro-Arg) but differ fundamentally in metabolic stability, CNS penetration, and breadth of biological activity
• For research procurement, prioritize suppliers providing ≥98% HPLC-verified purity, batch-specific COA, mass spectrometry confirmation, and proper cold-chain logistics